Ali Motamed‐Sanaye

Ali Motamed‐Sanaye

Auto-generated profile, based on publicly available information

Ali Motamed‐Sanaye

Student Research Committee Gonabad University of Medical Sciences Gonabad Iran

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2021 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
AAAmir R. Afshari
Amir R. Afshari
AMAli Motamed-Sanaye
Ali Motamed-Sanaye
HSHamed Sabri
Hamed Sabri
ASArash Soltani
Arash Soltani
SKSepideh KarkonShayan
Sepideh KarkonShayan
Amirhossein SahebkarAmirhossein Sahebkar
Amirhossein Sahebkar
The current standard of care in glioblastoma multiforme (GBM), as the most morbid brain tumor, is not adequate, despite substantial progress in cancer therapy. Among patients receiving current standard treatments, including surgery, irradiation, and chemotherapy, the overall survival (OS) period with GBM is less than one year. The high mortality frequency of GBM is due to its aggressive nature, including accelerated growth, deregulated apoptosis, and invasion into surrounding tissues. The understanding of the molecular pathogenesis of GBM is, therefore, crucial for identifying, designing, and repurposing potential agents in future therapeutic approaches. In recent decades, it has been apparent that several neurotransmitters, specifically substance P (SP), an undecapeptide in the family of neuropeptides tachykinins, are found in astrocytes. After binding to the neurokinin-1 receptor (NK-1R), the SP controls cancer cell growth, exerts antiapoptotic impacts, stimulates cell invasion/metastasis, and activates vascularization. Since SP/NK-1R signaling pathway is a growth driver in many cancers, this potential mechanism is proposed as an additional target for treating GBM. Following an evaluation of the function of both SP and its NK-1R inhibitors in neoplastic cells, we recommend a unique and promising approach for the treatment of patients with GBM.

11 June 2021 in Andrologia
Verified
Journal Article
Closed access
PDF file
REReza Elmimehr
Reza Elmimehr
AMAli Motamed‐Sanaye
Ali Motamed‐Sanaye
BBBalal Brazvan
Balal Brazvan
SSeyed-Hosein Abtahi-Eivary
Seyed-Hosein Abtahi-Eivary
MMMaryam Moghimian
Maryam Moghimian
MFMasoumeh Fani
Masoumeh Fani

2 December 2021 in Andrologia
Verified
Journal Article
Open access
PDF file
AMAli Motamed‐Sanaye
Ali Motamed‐Sanaye
REReza Elmimehr
Reza Elmimehr
BBBalal Brazvan
Balal Brazvan
SSeyed-Hosein Abtahi-Eivary
Seyed-Hosein Abtahi-Eivary
MMMaryam Moghimian
Maryam Moghimian
MFMasoumeh Fani
Masoumeh Fani
Click on the article title to read more.